23 reports

Porter Five Force Analysis ##.

  • Acne Treatment
  • Insulin Delivery
  • OTC
  • Therapy
  • Foamix Ltd.
  • 6.1 Global Acne Treatment Market Players by Product Comparison
  • 7.1.3 Business Strategy

First Choice (First Line Treatment) Alternative Treatment Maintenance Therapy Mild Moderate Severe ##) SYSTEMATIC THERAPY ##. ## Acne Treatment Systematic therapy refers to Acne medication that is taken by mouth.

  • Acne Treatment
  • Dermatological Condition
  • Therapy
  • Actavis plc
  • Foamix Ltd.
  • Pipeline Landscape Assessment
  • 5.2.3 Molecular Targets in the Pipeline

However, there are also two similar mAb therapies targeting mannan-binding lectin serine-protease-## (Masp##) and Masp##.

  • Blood Disease
  • Pathology
  • Therapy
  • La Jolla Pharmaceutical Company
  • Omeros Corporation
  • 3.2 The U.S. Rosacea Market Analysis
  • 5.1.3 Business Strategy

Oracea is one of the key brand of the company used in the treatment of rosacea.

  • Dermatological Condition
  • Therapy
  • United States
  • Market Size
  • Foamix Ltd.
  • Opportunities
  • ACNE VULGARIS - LATE-STAGE PIPELINE, 2017

SKIN THERAPY LETTER; ##(##): ##-##.

  • Acne Treatment
  • Anti-Infective
  • Therapy
  • World
  • Foamix Ltd.
  • EXECUTIVE SUMMARY
  • III. FOAMIX PHARMACEUTICALS LTD

It is one of the top ## brands in the overall acne therapy market.

  • Acne Treatment
  • Dermatological Condition
  • Therapy
  • Allergan plc
  • Foamix Ltd.
  • EXECUTIVE SUMMARY
  • III. FOAMIX PHARMACEUTICALS LTD

It is one of the top ## brands in the overall acne therapy market.

  • Acne Treatment
  • Dermatological Condition
  • Therapy
  • Allergan plc
  • Foamix Ltd.
  • 2.9 FMX101

Rising medical tourism is one of the major trends in skin care treatment.

  • Dermatological Condition
  • Pathology
  • Therapy
  • Forecast
  • Foamix Ltd.

During Solo-## and Solo-## patients were randomized ##:##:## to receive either placebo, Dupixent ##mg once weekly or ##mg Dupixent every other week with a placebo in-between.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Therapy
  • Foamix Ltd.
  • Key Patents in Acne Market Filing Year
  • III. Promising Drugs in Clinical Development

It is one of the top ## brands in the overall acne therapy market.

  • Acne Treatment
  • Dermatological Condition
  • Therapy
  • Allergan plc
  • Foamix Ltd.
  • Nov 25, 2019: La Jolla to Reassess continued development of LJPC-401 based on recent clinical results
  • Featured News & Press Releases

ISRs did not generally require treatment, and all but one resolved before study end.

  • Therapy
  • United States
  • World
  • Product Initiative
  • La Jolla Pharmaceutical Company
  • Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
  • La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC

Approximately ## patients in ## countries, including the U. S., will be randomized ##:## to receive either: (i) weekly subcutaneous injections of LJPC-##, while continuing standard-of-care chelation therapy (LJPC-## treatment arm)or (ii) a continuation of standard-

  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance
  • La Jolla Pharmaceutical Company
  • Foamix Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018
  • FOAMIX PHARMACEUTICALS LTD, PHARMACEUTICALS & HEALTHCARE, DEALS BY THERAPY AREA, 2012 TO YTD 2018

Patients are randomized ##:## to either ##% minocycline foam (FMX##) or vehicle, with once daily treatment for ## weeks.

  • Therapy
  • United States
  • Company
  • Company Operations
  • Foamix Ltd.
  • ANTIBIOTX APS
  • IMPETIGO - PIPELINE BY FOAMIX PHARMACEUTICALS LTD, H1 2018

Food and Drug Administration (FDA) seeking approval of ozenoxacin cream, ##%, nonfluorinated quinolone for the treatment of impetigo.

  • Anti-Infective
  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • Foamix Ltd.
  • vasopressor therapy. The trial was registered with the U.S National Institutes of Health.
  • FEATURED NEWS & PRESS RELEASES

This IND is for the treatment of patients with Type ## and Type ## hepatorenal syndrome.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • La Jolla Pharmaceutical Company
  • Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H1 2018
  • La Jolla Pharmaceutical Company

Patients will be randomized ##:## to receive either: (i) weekly subcutaneous injections of LJPC-##, while continuing standard-of-care chelation therapy (LJPC-## treatment arm); or (ii) a continuation of standard-of-care chelation therapy only (observation

  • Therapy
  • United States
  • World
  • Product Initiative
  • La Jolla Pharmaceutical Company
  • FEATURED NEWS & PRESS RELEASES
  • AMPRELOXETINE - DRUG PROFILE

Dopamine acts by agonising alpha-##- and beta-##- adrenergic receptors.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • La Jolla Pharmaceutical Company
  • FMX-103 - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

PATIENTS WERE RANDOMIZED INTO ONE OF FIVE TREATMENT GROUPS IN A ##:##:##:##:## RATIO: OMIGANAN ## PERCENT QD, OMIGANAN ##. ## PERCENT QD, OMIGANAN ##. ## PERCENT TWICE-DAILY (BID), VEHICLE QD, OR VEHICLE BID.

  • Therapy
  • United States
  • Company
  • Product Initiative
  • Foamix Ltd.

No one treatment can stand alone, " said Allan L.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • La Jolla Pharmaceutical Company
  • MIRVASO (Galderma)
  • 6.1 Foamix Pharmaceuticals Ltd.

Oracea is one of the key brand of the company used in the treatment of rosacea.

  • Dermatological Condition
  • Therapy
  • United States
  • Market Size
  • Foamix Ltd.
  • Heavy Metal Poisoning - Pipeline by La Jolla Pharmaceutical Company, H1 2018
  • LJPC-401 - Drug Profile

Patients will be randomized ##:## to receive either: (i) weekly subcutaneous injections of LJPC-##, while continuing standard-of-care chelation therapy (LJPC-## treatment arm); or (ii) a continuation of standard-of-care chelation therapy only (observation

  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • La Jolla Pharmaceutical Company
  • endpoints are safety, tolerability and efficacy in the treatment of moderate-to-severe papulopustular rosacea.
  • Foamix Pharmaceuticals Ltd. Overview

Foamix Ltd. is developing ciclopirox foam (ciclopiroxolamine ##%) for the treatment of dermatological fungal infections.

  • Therapy
  • United States
  • Company Operations
  • Product Initiative
  • Foamix Ltd.
  • La Jolla Pharmaceutical Company - Company Statement
  • LJPC-30Sb

This IND is for the treatment of patients with Type ## and Type ## hepatorenal syndrome.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Operations
  • La Jolla Pharmaceutical Company